TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
0.3213
+0.0150 (4.90%)
At close: Sep 15, 2026, 4:00 PM EDT
0.3220
+0.0007 (0.22%)
After-hours: Sep 15, 2026, 6:57 PM EDT
TScan Therapeutics Market Cap
TScan Therapeutics has a market cap or net worth of $21.78 million as of September 15, 2026. Its market cap has decreased by -78.20% in one year.
Market Cap
21.78M
Enterprise Value
12.51M
1-Year Change
-78.20%
Ranking
Category
Stock Price
$0.32
ChartMarket Cap Chart
Since the IPO on July 16, 2021, TScan Therapeutics's market cap has decreased from $359.08M to $21.78M, a decrease of -93.94%. That is a compound annual growth rate of -41.85%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 15, 2026 | 21.78M | -61.62% |
| Dec 31, 2025 | 56.75M | -66.96% |
| Dec 31, 2024 | 171.78M | -38.39% |
| Dec 29, 2023 | 278.82M | 647.03% |
| Dec 30, 2022 | 37.32M | -65.09% |
| Dec 31, 2021 | 106.93M | -70.22% |
| Jul 16, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Longeveron | 23.37M |
| NanoViricides | 23.24M |
| Polyrizon | 23.21M |
| Akari Therapeutics, | 22.00M |
| Jasper Therapeutics | 21.97M |
| Lantern Pharma | 21.86M |
| Cellectar Biosciences | 21.83M |
| Palatin Technologies | 21.07M |